Drugs / Prednisone
Prednisone
DrugPrednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive effects used across many disease categories. The Rayos label includes broad uses spanning allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, pulmonary, renal, rheumatologic, infectious, endocrine, neoplastic, and transplant-related conditions. U.S. labeling shows initial approval in 1955.
- Trials
- 1639
- Recruiting
- 189
- Completed
- 790
- With results
- 519
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 5 | 1 | 1 | 2 | 6 | 1 | — | — | 1 | — | — | 17 |
| Phase 1 | 15 | 4 | — | 17 | 73 | 20 | 7 | 1 | 6 | — | — | 143 |
| Phase 1/2 | 20 | 7 | 1 | 13 | 60 | 19 | 3 | 1 | 11 | — | — | 135 |
| Phase 2 | 71 | 22 | 1 | 48 | 304 | 66 | 27 | 2 | 62 | — | — | 603 |
| Phase 2/3 | 8 | 5 | 1 | 10 | 22 | 6 | 1 | 1 | 9 | — | — | 63 |
| Phase 3 | 36 | 8 | 3 | 36 | 192 | 42 | 12 | 1 | 36 | — | — | 366 |
| Phase 4 | 19 | 10 | 2 | 3 | 86 | 18 | 9 | 1 | 40 | — | — | 188 |
| Not applicable | 8 | 3 | — | 1 | 38 | 9 | 3 | — | 27 | — | — | 89 |
| Unknown | 7 | 1 | — | — | 9 | 2 | 2 | — | 11 | 1 | 2 | 35 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Prostatic Neoplasms | 1 | 25 | 29 | 121 | 5 | 56 | 3 | 1 | 4 | 245 |
| Lymphoma | — | 13 | 16 | 91 | 5 | 44 | 1 | 7 | 2 | 179 |
| Lymphoma, Large B-Cell, Diffuse | 2 | 25 | 22 | 80 | 5 | 35 | 1 | 6 | 1 | 177 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | — | 10 | 4 | 35 | 4 | 22 | 6 | 4 | 3 | 88 |
| Lymphoma, Follicular | — | 9 | 8 | 26 | 1 | 32 | — | 3 | 2 | 81 |
| Lymphoma, Non-Hodgkin | — | 10 | 11 | 25 | 1 | 22 | 1 | 3 | 1 | 74 |
| Burkitt Lymphoma | — | 16 | 5 | 32 | 2 | 13 | — | — | — | 68 |
| Multiple Myeloma | — | 5 | 10 | 26 | — | 19 | 2 | — | 2 | 64 |
| Leukemia | — | 5 | 3 | 27 | 3 | 17 | — | 3 | — | 58 |
| Hodgkin Disease | — | 4 | 5 | 24 | — | 12 | — | — | — | 45 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Cancer Institute (NCI) | 83 | 17 |
| 2 | M.D. Anderson Cancer Center | 49 | 3 |
| 3 | Children's Oncology Group | 34 | 20 |
| 4 | Janssen Research & Development, LLC | 34 | 13 |
| 5 | Hoffmann-La Roche | 30 | 13 |
| 6 | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 1 |
| 7 | Merck Sharp & Dohme LLC | 24 | 9 |
| 8 | SWOG Cancer Research Network | 24 | 9 |
| 9 | Sanofi | 20 | 12 |
| 10 | Assistance Publique - Hôpitaux de Paris | 19 | 8 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Prednisone | 1639 |
| 2 | Cyclophosphamide | 584 |
| 3 | Vincristine | 526 |
| 4 | Doxorubicin | 467 |
| 5 | Rituximab | 345 |
| 6 | Etoposide | 207 |
| 7 | Methotrexate | 174 |
| 8 | Dexamethasone | 159 |
| 9 | Cytarabine | 154 |
| 10 | Methylprednisolone | 147 |
Evidence
- Results reported
- 65.7%519 of 790 completed
- Published
- 25.7%203 of 790 completed
- Primary endpoint met
- 37.7%90 of 239 analyses
- Median months to report
- 14
Documents disclosed
Trial profile
- Median enrollment
- 71
- Median duration
- 55.1months
- Countries
- 90
- Study sites
- 24547
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 20
- Phase 1
- 25
- Phase 1/2
- 49
- Phase 2
- 53
- Phase 2/3
- 126
- Phase 3
- 267
- Phase 4
- 80
- Not applicable
- 74
- Unknown
- 113
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 276 |
| 2 | Houston | United States | 220 |
| 3 | Boston | United States | 214 |
| 4 | Chicago | United States | 200 |
| 5 | Seattle | United States | 174 |
| 6 | Baltimore | United States | 170 |
| 7 | Los Angeles | United States | 170 |
| 8 | St Louis | United States | 161 |
| 9 | Barcelona | Spain | 160 |
| 10 | Philadelphia | United States | 159 |
Terminations
- Terminated
- 183
- Withdrawn
- 64
- Suspended
- 7
- Stopped for recruitment
- 4.7%77 of 1639 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05934097 Withdrawn | Withdrawn | This study was withdrawn (Sponsor decision). | 2039-05-31 |
| NCT06692452 Withdrawn | Withdrawn | Ipsen requested a temporary closure due to a safety concern. | 2032-10-01 |
| NCT06952686 Withdrawn | Withdrawn | Study was Withdrawn per Sponsor decision. | 2032-03-30 |
| NCT06313996 Withdrawn | Withdrawn | Replaced with another clinical trial. | 2031-10-16 |
| NCT06392841 Withdrawn | Withdrawn | Funder withdrew funding. | 2029-01-31 |
| NCT06329830 Withdrawn | Withdrawn | Funding for the study was withdrawn. | 2028-10-31 |
| NCT04415476 Withdrawn | Withdrawn | Study did not proceed to IRB approval. | 2028-06-30 |
| NCT06527690 Withdrawn | Withdrawn | The study aimed to include multiple countries in Latin America, but only Brazil was feasible, making the intended ethnic and racial design unviable. Activities were closed and no sites were opened for recruitment. | 2028-02-28 |
| NCT05279300 Suspended | Suspended | The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule. | 2027-12-31 |
| NCT04974996 Withdrawn | Withdrawn | Decision to not proceed with study. | 2027-05-05 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: